DDL Diagnostic Laboratory and ENPICOM Join Forces to Deliver Unique Immune Repertoire Sequencing and Data Analysis Services
A full-service offering to accelerate immunotherapy discovery and development.
Rijswijk, Netherlands, May 09, 2019 --(PR.com)-- Two Dutch companies - DDL, a state-of-the- art laboratory specializing in molecular diagnostic testing and assay development and ENPICOM, an innovative immunomics data analysis company - today announced that they have started a collaboration to jointly deliver immune repertoire sequencing and analysis service to organizations studying immune system related diseases or developing drugs influencing this system.
Immune repertoire sequencing is a powerful way to analyze hundreds of thousands to millions of T or B cell receptors swiftly and in a cost-effective way. This new technology is rapidly gaining interest from researchers and physicians who want to unravel the adaptive immune responses in areas like basic and translational immunology, immuno-oncology, autoimmune disorders, inflammatory and infectious diseases, vaccine research and transplantation. From target discovery to patient stratification in clinical trials with immunotherapies, repertoire sequencing is becoming an important addition to accelerate the different drug development processes and make it more cost-effective.
“DDL is very pleased to start this partnership with ENPICOM in this new and challenging field of immunomics,” says Jan Lindeman, DDL’s Chief Executive Officer. “It further expands DDL’s portfolio of tailor-made molecular diagnostic services for our (bio)pharmaceutical customers. ENPICOM’s expertise and know-how are highly complementary to DDL’s expertise and we are confident that this partnership will offer a unique opportunity to accelerate immunotherapy discovery and development.”
Jos Lunenberg, ENPICOM’s Chief Executive Officer comments, “Last month we launched our IGX platform to manage, store, analyze, visualize and interpret immune repertoire sequencing data from T and B cell receptors. Now we are also able to support organizations lacking the specific expertise or capabilities to perform repertoire sequencing with our smart new analysis and visualization methods. In DDL we have found a highly respected business partner with an excellent track record as molecular diagnostic testing laboratory for the biopharmaceutical industry. I’m very pleased to be able to go public with this partnership today.” He continues, “There are a few other kits and services for this specific form of targeted sequencing available in the market, but none or very limited data analysis is included. Clonality analysis is just a first step to bridge the existing gap between producing raw sequencing data and obtaining important insights from the data. So, in essence, we start where others stop.”
About DDL Diagnostic Laboratory
DDL Diagnostic Laboratory is a state-of-the-art laboratory specialized in (molecular) diagnostic testing and diagnostic assay development. DDL performs advanced assays (including next-generation sequencing) on behalf of pharmaceutical companies and clinical laboratories, primarily, within the complex framework of preclinical studies and Phase II-IV clinical trials. Currently, DDL serves multiple international pharmaceutical companies, including 10 of the global Top-20. DDL also designs, develops and validates diagnostic assays, which can be customized for specific diagnostic purposes.
Our fascination for science, solving complex problems, and making the world a healthier place, drives us. We focus on quality, knowledge and customer service. It is our mission to enable our customers to make a positive impact on human health today and for next generations.
To learn more visit www.ddl.nl and follow us on LinkedIn.
About ENPICOM
ENPICOM is an innovative immunomics data analysis company with an outstanding team of professionals. They focus on supporting immunotherapy developers with groundbreaking products and customized solutions to improve and accelerate discovery and development of novel immunotherapies. Clinical validation projects to stratify patients and monitor treatment responses to immunotherapies under development are ongoing.
ENPICOM’s first product on the market is a world-class repertoire sequencing data analysis solution, the ImmunoGenomiX (IGX) platform. IGX is an innovative platform to manage, store, analyze, visualize and interpret immune repertoire sequencing data from T and B cell receptors. The smart new analysis and visualization methods are also offered as IGX-service. In collaboration with DDL Diagnostic Laboratory also in a full-service proposition to organizations lacking the specific expertise or capabilities to perform repertoire sequencing.
For more information, visit www.enpicom.com and follow us on LinkedIn.
Contacts
DDL Diagnostic Laboratory
Jan Lindeman (CEO)
Visseringlaan 25 2288 ER Rijswijk
The Netherlands
Jan.Lindeman@ddl.nl
+31 88 23533333
ENPICOM
Jos Lunenberg (CEO)
Oranje Nassaulaan 28A 5211 AX's-Hertogenbosch
The Netherlands
j.lunenberg@enpicom.com
+31 85 2500575
Immune repertoire sequencing is a powerful way to analyze hundreds of thousands to millions of T or B cell receptors swiftly and in a cost-effective way. This new technology is rapidly gaining interest from researchers and physicians who want to unravel the adaptive immune responses in areas like basic and translational immunology, immuno-oncology, autoimmune disorders, inflammatory and infectious diseases, vaccine research and transplantation. From target discovery to patient stratification in clinical trials with immunotherapies, repertoire sequencing is becoming an important addition to accelerate the different drug development processes and make it more cost-effective.
“DDL is very pleased to start this partnership with ENPICOM in this new and challenging field of immunomics,” says Jan Lindeman, DDL’s Chief Executive Officer. “It further expands DDL’s portfolio of tailor-made molecular diagnostic services for our (bio)pharmaceutical customers. ENPICOM’s expertise and know-how are highly complementary to DDL’s expertise and we are confident that this partnership will offer a unique opportunity to accelerate immunotherapy discovery and development.”
Jos Lunenberg, ENPICOM’s Chief Executive Officer comments, “Last month we launched our IGX platform to manage, store, analyze, visualize and interpret immune repertoire sequencing data from T and B cell receptors. Now we are also able to support organizations lacking the specific expertise or capabilities to perform repertoire sequencing with our smart new analysis and visualization methods. In DDL we have found a highly respected business partner with an excellent track record as molecular diagnostic testing laboratory for the biopharmaceutical industry. I’m very pleased to be able to go public with this partnership today.” He continues, “There are a few other kits and services for this specific form of targeted sequencing available in the market, but none or very limited data analysis is included. Clonality analysis is just a first step to bridge the existing gap between producing raw sequencing data and obtaining important insights from the data. So, in essence, we start where others stop.”
About DDL Diagnostic Laboratory
DDL Diagnostic Laboratory is a state-of-the-art laboratory specialized in (molecular) diagnostic testing and diagnostic assay development. DDL performs advanced assays (including next-generation sequencing) on behalf of pharmaceutical companies and clinical laboratories, primarily, within the complex framework of preclinical studies and Phase II-IV clinical trials. Currently, DDL serves multiple international pharmaceutical companies, including 10 of the global Top-20. DDL also designs, develops and validates diagnostic assays, which can be customized for specific diagnostic purposes.
Our fascination for science, solving complex problems, and making the world a healthier place, drives us. We focus on quality, knowledge and customer service. It is our mission to enable our customers to make a positive impact on human health today and for next generations.
To learn more visit www.ddl.nl and follow us on LinkedIn.
About ENPICOM
ENPICOM is an innovative immunomics data analysis company with an outstanding team of professionals. They focus on supporting immunotherapy developers with groundbreaking products and customized solutions to improve and accelerate discovery and development of novel immunotherapies. Clinical validation projects to stratify patients and monitor treatment responses to immunotherapies under development are ongoing.
ENPICOM’s first product on the market is a world-class repertoire sequencing data analysis solution, the ImmunoGenomiX (IGX) platform. IGX is an innovative platform to manage, store, analyze, visualize and interpret immune repertoire sequencing data from T and B cell receptors. The smart new analysis and visualization methods are also offered as IGX-service. In collaboration with DDL Diagnostic Laboratory also in a full-service proposition to organizations lacking the specific expertise or capabilities to perform repertoire sequencing.
For more information, visit www.enpicom.com and follow us on LinkedIn.
Contacts
DDL Diagnostic Laboratory
Jan Lindeman (CEO)
Visseringlaan 25 2288 ER Rijswijk
The Netherlands
Jan.Lindeman@ddl.nl
+31 88 23533333
ENPICOM
Jos Lunenberg (CEO)
Oranje Nassaulaan 28A 5211 AX's-Hertogenbosch
The Netherlands
j.lunenberg@enpicom.com
+31 85 2500575
Contact
ENPICOM BV
Jos Lunenberg
+31 85 250 0575
www.enpicom.com
Jos Lunenberg
+31 85 250 0575
www.enpicom.com
Contact
Categories